Fisher Biosciences strengthens its reagent portfolio through acquisition of BioImage

29-May-2006

Fisher Biosciences has acquired BioImage to expand its offering in high content screening and analysis reagent technologies. BioImage complements Fisher Biosciences' existing Cellomics business. The Cellomics platform includes automated imaging instrumentation, BioApplication image analysis software, High Content informatics software and reagent kits. The entire Cellomics product portfolio is fully integrated to improve the quality and productivity of high content cellbased assays. BioImage is a leader in the field of High Content Pathway analysis, providing the life-science market with products, services and licenses that are based on its Redistribution® technology. Redistribution is a patented technology that monitors protein translocation within a cell and is the basis for many of today's high content assays.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances